ALMS · Alumis Inc. · Stock research

"# ALMS — Alumis Inc.

Current Thesis

The psoriasis leg of this story is finished being told. On 2026-08-10 Alumis released ONWARD3 long-term-extension topline showing 75% of patients at PASI 90 and 54% at PASI 100 after up to 48 weeks of continuous envudeucitinib (n=773) — the strongest durability dataset the company has produced — and the stock closed 2026-08-14 at $25.31, 16.5% below its 52-week high of $30.30. Good clinical news is now being absorbed rather than extended. What remains buyable is one undated event: the potentially pivotal LUMUS Phase 2b topline in systemic lupus erythematosus, reaffirmed for Q3 2026 on the 2026-08-13 Q2 release. A clean primary-endpoint hit opens the type-I interferon axis (Sjögren's and cutaneous lupus are already named as follow-ons) and re-rates envudeucitinib beyond dermatology; a miss leaves a well-characterised oral psoriasis pill entering a field where Sotyktu is entrenched and Takeda's zasocitinib is advancing. Enrollment is complete and the guided window closes 2026-09-30, so headline risk is any-session.

The narrative is maturing. The dating: the 2026-01-06 Phase 3 psoriasis topline produced a +95.31% single session and drove the twelve-month re-rate; full Phase 3 data on 2026-03-28 extended it; but the 2026-08-10 48-week extension data did not carry price back toward $30.30, and HC Wainwright moved from Buy to Neutral on valuation with a $25 target reiterated on both 2026-08-03 and 2026-08-14. Dense coverage, incrementally positive data, no new high — the flow is moderating while the story still works.

Bullish and bearish views on Alumis Inc.

The model's bull view on Alumis Inc. (ALMS), in brief: Durability now demonstrated (2026-08-10): ONWARD3 LTE topline — 75% PASI 90 and 54% PASI 100 after up to 48 weeks, n=773. The bear view: Q2 2026 missed on both lines (2026-08-13): EPS $(1.11) against $(0.71) consensus; revenue $1.662M against $3.468M consensus. Both cases follow in full.

Bull Case

• Durability now demonstrated (2026-08-10): ONWARD3 LTE topline — 75% PASI 90 and 54% PASI 100 after up to 48 weeks, n=773. This addresses the standard objection to Week-16/Week-24 clearance data and feeds the NDA package.
• Phase 3 efficacy (full data 2026-03-28): PASI 90 68.0%/62.1% and PASI 100 41.0%/39.5% at Week 24 across ONWARD1/ONWARD2.
• Regulatory step on the calendar: NDA submission to FDA for moderate-to-severe plaque psoriasis remains on track for Q4 2026, reaffirmed 2026-08-13.
• Funded through both events: $502.3M cash, cash equivalents and marketable securities at 2026-06-30, with stated runway into Q4 2027 — no forced raise before the lupus print.
• Cost line moving the right way: Q2 2026 R&D $85.3M versus $108.8M in Q2 2025; G&A $23.4M versus $34.5M.
• Indication optionality is pre-specified: Sjögren's disease and cutaneous lupus erythematosus named as the next interferon-driven targets, contingent on LUMUS; a Phase 2 biomarker trial of A-005 (CNS-penetrant TYK2) in Parkinson's is planned for H1 2027.
• Street still above the tape: 11 analysts polled by S&P Global carry a Strong Buy consensus and an average target of $39.9.

Bear Case

• Q2 2026 missed on both lines (2026-08-13): EPS $(1.11) against $(0.71) consensus; revenue $1.662M against $3.468M consensus. Net loss for the quarter was $142.2M.
• The sell-side is no longer uniformly bullish: HC Wainwright downgraded to Neutral citing valuation and has reiterated Neutral/$25 twice this month (2026-08-03, 2026-08-14) — a published target sitting essentially on top of the 2026-08-14 close of $25.31, against a $39.9 consensus average. That dispersion is the disagreement about what lupus is worth.
• Best data of the year did not make a new high: the 2026-08-10 release left price 16.5% under $30.30 four sessions later.
• LUMUS is Phase 2b in SLE, historically the hardest immunology indication to read out cleanly; the trial is potentially pivotal, not confirmatory.
• Pre-revenue with a large burn: the only reported top line is $1.7M of collaboration revenue in Q2 2026, against a $142.2M quarterly net loss.
• Crowded oral TYK2 field: BMS's Sotyktu is the commercial incumbent; Takeda's zasocitinib is a competing next-generation molecule. Cross-trial clearance advantage does not settle formulary access or price.
• Equity funding into strength is the pattern: a $17.00 follow-on of 20.3M shares closed 2026-01-09, days after the January re-rate.

Setup & Price Structure

• Reference close 2026-08-14: $25.31. 52-week high $30.30 (-16.5%). Three-month return +10.7%. RSI(14) 42.9 — mid-range, no overbought extension into the readout window.
• The April–June advance built a rising base from roughly $20 into the high $20s. $22 is the floor of that structure; the stock trading below the late-July high-$20s area means the market has already given back part of the summer premium ahead of the binary.
• Positioning observables, stated as observables: news flow clustered — five headlines between 2026-08-03 and 2026-08-14, including a beat-quality clinical release and an earnings miss — with no new high out of it. The Q2 print is behind (2026-08-13), so there is no scheduled earnings date inside the next 30 days; the entire positioning question sits on an undated 8-K. The most recently published target ($25, 2026-08-14) is at the market; the consensus average ($39.9) is far above it.
• No new equity filings appear in the recent record, but the January precedent means a post-readout financing is a live possibility either way the data breaks.

Catalyst Calendar (next 30 days)

• ~2026-09-15 (est.) — LUMUS Phase 2b SLE topline. Company guidance is "third quarter of 2026" (reaffirmed 2026-08-13); this date is a mid-window placeholder, not a confirmed release date. Any session from now is live.
• 2026-09-30 — hard outer edge of the guided Q3 window. If the quarter ends without topline, the guidance itself is the datapoint.
• Ongoing — competitor read-across. Any zasocitinib or Sotyktu dataset or label action can reprice ALMS with nothing coming from Alumis.
• Outside the window but relevant: Q4 2026 NDA submission for plaque psoriasis; H1 2027 Phase 2 biomarker trial start for A-005 in Parkinson's.

What Would Change Our Mind

The structure that has to hold is the April–June base. Its floor is $22: a weekly close below $22 would mean the entire summer advance has been round-tripped and the market is discounting the lupus print negatively before it lands, which is a different situation from waiting on a coin-flip. Second, if 2026-09-30 passes with no LUMUS topline and the company re-guides, the undated-binary frame becomes a timing-slip frame and the name reverts to a psoriasis-launch story that has to be valued on commercial assumptions rather than optionality. Third, on the data itself: a primary-endpoint miss in LUMUS caps envudeucitinib in dermatology and removes the reason the stock carries a $39.9 consensus average. Conversely, a clear hit with a clean safety profile — and target revisions from the analysts currently sitting at $25 — would flip the read-through from binary-event to franchise. Fresh entries at $25.31 into an undated Phase 2b in SLE are a coin-flip on timing as well as outcome; the case for waiting for either the print or a lower base is stronger than the case for anticipating.

Correlation Notes

• TYK2 complex: ALMS trades with read-across to BMS (Sotyktu, the commercial benchmark it is measured against) and Takeda (zasocitinib). A competitor efficacy or safety print moves ALMS without any Alumis news.
• Clinical-stage biotech beta: long-duration, pre-revenue names track XBI-style risk appetite and rate expectations; a $142.2M quarterly loss against $502.3M of cash makes financing-window sentiment a direct input.
• Idiosyncratic dominance: the 2026-01-06 +95.31% single session shows event risk swamps factor exposure here. Any published beta for this name is distorted by that gap and should not be read as a macro relationship."